|
[posting]27653108[/posting]Swinburne ergebnisse und Ropren zulassung werden diese aktie explodieren lassen. Läuft alles nach plan sind in kürze kurse zwischen 2$-3$ realistisch. Bioeffective R - Neurodegenerative Disorders Target Market: Alzheimer\'s Disease, Parkinson\'s Target Date: Current Swinburne trials to finish Q4 CY06 BUSINESS A pine scented panacea JOHN BEVERIDGE 372 words 1 February 2007 Herald-Sun "THERE are plenty of sombre warnings around about the dramatically increasing cost of dealing with dementia in Australia. This week the Australian Institute of Health and Welfare found that it cost about $1.4 billion to look after Australia's 175,000 dementia sufferers in 2003. And it predicts that will rise to 465,000 people by 2031 at a cost of $3.5 billion. The one ray of sunshine in this otherwise gloomy picture is the large number of medical trials going on that hold great promise of at least delaying the onset of the various forms of dementia. One that has kept a fairly low profile is in the final stages of testing by Melbourne biotechnology company Solagran. Using polyprenols first isolated from green conifer needles by Professor Victor Roschin back in 1986, Ropren has enjoyed some positive trial results. Memory and cognitive function have improved by 15 to 20 per cent in healthy elderly volunteers. Since listing in 2003, Solagran has been testing the effectiveness of Ropren in treating chronic liver disease, immune system enhancement and neurodegenerative disorders. Russian regulatory approval for use in treating liver disease is expected by March and the drug is being prepared for full-scale production in St Petersburg. There are 10 million Russians with chronic liver disease so demand for that purpose is expected to be significant. Russian doctors are also hoping to use the drug to treat psychological conditions in drug and alcohol-addicted patients. Once commercial production increases, Solagran will also be able to directly supply three month courses of the drug for personal use to people in Australia, the US and other countries on application. One interesting finding in the drug trials was the ability of Ropren to normalise cholesterol levels in the blood without the usual side effects of cholesterol lowering drugs. That suggests a significant "off label" market for the drug. There is also evidence it may delay the onset of dementia in susceptible patients as well as treating its symptoms once the problem has been diagnosed. |
|
| aus der Diskussion: | Solagran - jetzt schnell noch einsteigen |
| Autor (Datum des Eintrages): | BrauchGeld (12.02.07 13:37:21) |
| Beitrag: | 150 von 872 (ID:27658872) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |